Michael Paley, M.D., Ph.D. (moving to @Bluesky)

Ocular Rheumatologist | @WUSTL_Rheum @WUDeptMedicine | T cell biology and scRNAseq/TCRseq | full of dry and nerdy humor

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

We are thrilled to have been part of a multi-institutional, multidisciplinary group to identify disease-associated T cells in #AnkylosingSpondylitis & Anterior #Uveitis that recognize antigens presented by HLA-B27, published in @Nature. (1/9)

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

Thank you, @KilianMD, for inviting me to speak at St. Louis University's Rheum Grand Rounds this morning! It's always great to see our neighbors to the East and talk shop!

@WashUMedRheum #Rheumatology

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

I’m moving to @bluesky!

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

@peter_morawski Thanks. I will need to take a look!

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

Excited to share new findings from my #Spondylitis research! Join me & Dr. Barhram Razani in the @CureArthritis Research Spotlight Series on 9/18. We’ll discuss the latest treatment breakthroughs & research. Register today: https://t.co/lY87UIAClY #PsA #ArthritisResearch

[JCI insight @JCI_insight]

An enteric start to HLA-B27-associated autoimmune disease? https://t.co/TyE7kuaxkg

Work from @drmapaley, @XinboYang777 et al. suggests early antigen exposure in gut leads to pathogenic CD8+ T cell development in axial spondyloarthritis & acute anterior uveitis.
@WUSTLmed

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

@MaxKonigMD In our data so far, about 75% of the TCRs use TRBV9, and other TRBVs (5,7,etc.) make up the rest. We have a uveogenic TRBV5-5 TCR, so I think we can imagine they are arthrithrogenic as well, but will need more data.

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

(1/7)Excited to see our latest manuscript in press at @JCI_insight (https://t.co/b79az7jSt0)! This was a great extension of our continuing multi-institutional, multidisciplinary group to better understand pathogenic CD8 T cells in #axialspondyloarthritis & anterior #uveitis.

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

(7/7) As always, we must thank key funders who supported this campaign to better understand and treat #spondylitis and #uveitis: @RheumResearch, @CureArthritis, @NIH_NIAMS, #HHMI.

@wustl_rheum @WUDeptMedicine

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

(6/7) We think that more in depth TCR profiling will be needed to stratify patients prior to selecting therapies like BCD180.

[The New York Times @nytimes]

Pharmacy benefit managers act as middlemen overseeing prescriptions for millions of Americans to reduce drug costs. A New York Times investigation found they charge steep prices for patients, employers and the government. Our reporter explains how. https://t.co/vEwmFFI2Ou

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

@RuthJeanNapier @LUveitis @rheum_cat @MohamadBittarMD @tejpalgill If it was, that would pretty much ruin a HLA-B27+ healthy cohort.

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

Really enjoyed the invitation to be on Spondycast and talk about where we are for #HLA-B27 research for #axSpA and #Uveitis and where we might be going. Really excited about the possibility of new #Diagnostics and #Therapeutics.

@spondylitis

[Spondylitis.org @spondylitis]

🎙Dive into the latest episode of Spondycast, where host Jill Miller & award-winning ocular rheumatologist @drmapaley enlighten us on his groundbreaking research! Check it out here: https://t.co/vYhcCKQvhC #inflammation #uveitis #gut #microbiome

[Spondylitis.org @spondylitis]

🎙Dive into the latest episode of Spondycast, where host Jill Miller & award-winning ocular rheumatologist @drmapaley enlighten us on his groundbreaking research! Check it out here: https://t.co/vYhcCKQvhC #inflammation #uveitis #gut #microbiome

[Saligrama lab_WUSTL @SaligramaLab]

"total number of TCRs in a human, supports Mason’s notion that we should #abandon the ‘one-clonotype–one-specificity’ paradigm suggested by clonal selection theory in favour of a ‘one-clonotype–millions-of‑specificities’reality" https://t.co/sSQdCmN6QV

[Michael Paley, M.D., Ph.D. (moving to @Bluesky) @drmapaley]

Check out our new lab website: https://t.co/XFhuR9r6F6

#Research

[Lacey Feigl (moved to @Bluesky @LaceyFeigl) @LaceyFeigl]

Thank you, @spondylitis, for awarding Dr. Michael Paley with this years ECI Award! We are so proud of the work he does to help those suffering from #SpA related diseases! ❤️

@drmapaley #ACR23